NCT06938152View on ClinicalTrials.gov

Effects of Cycle Therapy vs Sequential Therapy With Romosozumab and Denosumab in Postmenopausal Osteoporosis Patients

PHASE4RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

April 8, 2025

Primary Completion Date

April 15, 2029

Study Completion Date

December 31, 2029

Conditions
OsteoporosisOsteoporosis Postmenopausal
Interventions
DRUG

Romosozumab followed by Denosumab

Romosozumab 210mg/month for 12 months, then Denosumab 60mg/6months for 12 months

DRUG

Romosozumab and Denosumab Cycle Therapy

Romosozumab 210mg/month for 6 months then followed by Denosumab 60mg/6months once, and then repeat one more time after 6 months

Trial Locations (1)

Unknown

RECRUITING

National Taiwan University Hospital, Taipei

All Listed Sponsors
lead

National Taiwan University Hospital

OTHER